New York, NY, March 18, 2019 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Breast Cancer Drugs Market by Drug Type (Hormone Therapy, Chemotherapy Drugs, Targeted Therapy Drugs, and Other Therapeutic Drugs): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global breast cancer drugs market was valued at approximately USD 18.8 billion in 2018 and is expected to generate around USD 38.3 billion by 2025, at a CAGR of around 10.55% between 2019 and 2025.
Breast cancer is the result of uncontrolled cell division of breast cells, most commonly cells of breast lobule and ducts. It may also affect fatty or connective tissues within the breasts. Breast cancer is the second most common type of cancer worldwide, affecting nearly 2 million women.
Browse through 20 Tables & 17 Figures spread over 110 Pages and in-depth TOC on “Global Breast Cancer Drugs Market Size & Share 2018: Industry Research Report, Growth, Segment, Analysis, and Forecast up to 2025”.
Request Free Sample Report of Global Breast Cancer Drugs Market Report @ https://www.zionmarketresearch.com/sample/breast-cancer-drugs-market
The increasing breast cancer prevalence worldwide is the major driving factor for the global breast cancer drugs market along with increasing health awareness, healthcare spending, and rising disposable income of people. Investments made by major market players for novel drug development and favorable reimbursement policies are also contributing to the breast cancer drugs market globally. Additionally, government funding/grants for research and development and patent expiry will further propel this market’s growth in the future. However, the high cost of treatment may hamper the breast cancer drugs market growth.
The global breast cancer drugs market segments are based on drug type and region. Based on drug type, the market is segmented into chemotherapy drugs, hormone therapy drugs, targeted therapy drugs, and other therapeutic drugs. Chemotherapy drugs held the largest market share in 2018, whereas targeted therapy drugs are expected to show the highest CAGR over the forecast time period. Targeted therapy helps the immune system destroy cancer cells by interfering with specific proteins and fights the cancer cells only along with having lesser side effects as compared to chemotherapeutic drugs. This will fuel the targeted therapy drugs’ market popularity over the estimated timeframe.
Download Free Report PDF Brochure: https://www.zionmarketresearch.com/requestbrochure/breast-cancer-drugs-market
Chemotherapy drugs are sub-segmented into anthracyclines, taxanes, antimetabolites, alkylating agents, and epothilones. Anthracyclines segment is split into doxorubicin and epirubicin. Taxanes are split into paclitaxel and docetaxel. Antimetabolites segment is classified into fluorouracil, capecitabine, and gemcitabine. Hormone therapy drugs are classified into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and other hormonal therapies. Selective estrogen-receptor modulators segment is further split into tamoxifen, raloxifene, and toremifene. Aromatase inhibitors segment is split into letrozole, anastrozole, and megestrol. Other hormonal therapy drugs include goserelin acetate, fulvestrant, fluoxymesterone etc. The targeted therapy drugs are classified into monoclonal antibodies (mAbs) and tyrosine kinase inhibitors. Monoclonal antibodies (mAbs) are further split into bevacizumab, trastuzumab, and other mAbs.
By region, North America dominated the global breast cancer drugs market with a market share of about 43% in 2018 and is projected to retain its leading position over the forecast time period as well. This can be attributed to the increasing prevalence of breast cancer, growing health awareness, the presence of key market players in the region, ongoing drug discovery research and development projects, favorable reimbursement policies for breast cancer, increasing use of breast cancer targeted therapies as precision medicine, presence of developed healthcare infrastructure, and increasing health awareness and spending. At the country level, the U.S. is a major country for the North American breast cancer drugs market followed by Canada. In 2018, the U.S. dominated this regional with the largest market share, i.e., about 80%, owing to the high disease burden of breast cancer, changing lifestyle and dietary habits, and technological advancements.
Browse the full “Breast Cancer Drugs Market by Drug Type (Hormone Therapy, Chemotherapy Drugs, Targeted Therapy Drugs, and Other Therapeutic Drugs): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/breast-cancer-drugs-market
Europe held the second largest market share in 2018 of the global breast cancer drugs market, owing to the growing adoption of targeted therapies, increasing breast cancer prevalence, favorable reimbursement policies, and developed healthcare infrastructure. Germany, France, and UK are major countries of the European breast cancer drugs market. UK is estimated to show the highest CAGR over the forecast time period. Germany contributed the largest revenue share, about 34%, to the European breast cancer drugs market followed by UK.
Asia Pacific is projected to witness the highest CAGR over the forecast time period in the global breast cancer drugs market, due to the growing health awareness, increasing disposable income, and rising healthcare spending, increasing breast cancer burden. Large geriatric population base and increasing biopharmaceutical drug development and research activities are also expected to contribute to the breast cancer drugs market in this region. China and Japan represent the dominating countries of the Asia Pacific breast cancer drugs market. China contributed 35% revenue share to the Asia Pacific breast cancer drugs market, whereas Japan held the second largest market share in 2018. India is expected to be the fastest growing country in the region over the forecast timeline.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/breast-cancer-drugs-market
Latin America is another important regional market for breast cancer drugs, which is projected to register moderate growth over the forecast period. Brazil held the largest revenue share of about 65% in 2018 and is the major market in Latin America breast cancer drugs. The Middle Eastern and African breast cancer drugs market will register considerable growth in the upcoming years, owing to poor healthcare infrastructure and lack of awareness.
Some key players of the global breast cancer drugs market include AbbVie, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Celgene Corporation, Eli Lilly and Company, Merck & Co., Inc., Biocon, Genzyme Corporation, MacroGenics, Inc., Janssen Global Services LLC, Onyx Pharmaceuticals Inc., Celldex Therapeutics, and BioNumerik Pharmaceuticals, Inc.
Request customized copy of report @ https://www.zionmarketresearch.com/custom/70
This report segments the global breast cancer drugs market into:
Global Breast Cancer Drugs Market: By Drug Type
- Chemotherapy Drugs
- Anthracyclines
- Doxorubicin
- Epirubicin
- Taxanes
- Paclitaxel
- Docetaxel
- Antimetabolites
- Fluorouracil
- Capecitabine
- Gemcitabine
- Alkylating Agents
- Epothilones
- Anthracyclines
- Hormone Therapy Drugs
- Selective Estrogen-Receptor Modulators (SERMs)
- Tamoxifen
- Raloxifene
- Toremifene
- Aromatase Inhibitors
- Letrozole
- Anastrozole
- Megestrol
- Other Hormonal Therapies
- Goserelin acetate
- Fulvestrant
- Fluoxymesterone
- Selective Estrogen-Receptor Modulators (SERMs)
- Targeted Therapy Drugs
- Monoclonal Antibodies (mAbs)
- Bevacizumab
- Trastuzumab
- Other mAbs
- Tyrosine kinase inhibitors
- Monoclonal Antibodies (mAbs)
- Other Therapeutic Drugs
Global Breast Cancer Drugs Market: By Region
- North America
- The U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- The Middle East and Africa
Related Reports:
- Cannabis Oil Market: https://www.zionmarketresearch.com/report/cannabis-oil-market
- Animal Wound Care Market: https://www.zionmarketresearch.com/report/animal-wound-care-market
- Corporate Wellness Market: https://www.zionmarketresearch.com/report/corporate-wellness-market
- Digital Diabetes Management Market: https://www.zionmarketresearch.com/report/digital-diabetes-management-market
- Chronic Disease Management Market: https://www.zionmarketresearch.com/report/chronic-disease-management-market
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research
Blog: http://zmrindustryjournal.us | http://zmrresearchnews.us | http://zmrmarketjournal.com | https://zmrnewsjournal.us | http://zmrnewsmagazine.com | https://zmrnewsblog.com
Contact Us:
Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com
Blog: http://zmrblog.com